Post hoc clinical effectiveness analyses
The CARAT questionnaire is a validated useful tool for facilitating
optimal control of both asthma and allergic rhinitis simultaneouslyand
is described in a recent EAACI position paper and included in Dutch
guidelines. CARAT scores vary from 0 points (worst) to 30 points (best)
outcome. The minimal clinical important difference (MCID) for CARAT
scores was established at a 4 points difference in 2015. Changes equal
or more than MCID, with a P <0.05 for difference in
means, were considered indicative for clinical effectiveness.